JPRN-UMIN000048396Completed未知
Investigation of the immunogenicity and durability of second COVID-19 vaccine booster dose and their associations with the background factors - Investigation of the immunogenicity and durability of second COVID-19 vaccine booster dose and their associations with the background factors
Department of Pulmonology and Gerontology, Graduate School of Medicine, Yamaguchi University0 sites100 target enrollmentStarted: July 20, 2022Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Those who do not wish to be vaccinated with second COVID-19 vaccine booster dose. 2) Those who are judged to be inappropriate for registration at the discretion of the doctor in charge.
Investigators
Similar Trials
Completed
Phase 3
Durability of Immunogenicity and Effectiveness of the heterologous COVID-19 vaccination in kidney transplant recipientsImmunogenicity of the vaccineEffectiveness of the vaccinehumoral immunity, cell-mediated immunity, SARS-CoV-2, immunization, immunocompromisedTCTR20220511002ational Council Researach of Thailand100
Active, not recruiting
Phase 1
Evaluation of How Long Immune Responses to SARS-CoV-2 Persist Following COVID-19 VaccinatioCOVID-19EUCTR2021-000349-42-SESahlgrenska Academy, University of Gothenburg500
Active, not recruiting
Early Phase 1
The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002COVID-19NCT05928468Guangzhou Patronus Biotech Co., Ltd.210
Active, not recruiting
Not Applicable
A Long Term Safety and Effectiveness Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)HPVMedDRA version: 18.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2014-005717-23-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,575
Active, not recruiting
Not Applicable
A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV-013. - HPV-025 EXT 013For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.EUCTR2008-000369-44-DEGlaxoSmithKline Biologicals600